Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jeffrey J TosoianH Ballentine Carter

Abstract

To assess long-term outcomes of men with favorable-risk prostate cancer in a prospective, active-surveillance program. Curative intervention was recommended for disease reclassification to higher cancer grade or volume on prostate biopsy. Primary outcomes were overall, cancer-specific, and metastasis-free survival. Secondary outcomes were the cumulative incidence of reclassification and curative intervention. Factors associated with grade reclassification and curative intervention were evaluated in a Cox proportional hazards model. A total of 1,298 men (median age, 66 years) with a median follow-up of 5 years (range, 0.01 to 18.00 years) contributed 6,766 person-years of follow-up since 1995. Overall, cancer-specific, and metastasis-free survival rates were 93%, 99.9%, and 99.4%, respectively, at 10 years and 69%, 99.9%, and 99.4%, respectively, at 15 years. The cumulative incidence of grade reclassification was 26% at 10 years and was 31% at 15 years; cumulative incidence of curative intervention was 50% at 10 years and was 57% at 15 years. The median treatment-free survival was 8.5 years (range, 0.01 to 18 years). Factors associated with grade reclassification were older age (hazard ratio [HR], 1.03 for each additional year; ...Continue Reading

References

May 5, 2005·JAMA : the Journal of the American Medical Association·Peter C AlbertsenJudith Fine
Sep 19, 2006·Journal of Clinical Epidemiology·Danielle A SouthernUNKNOWN APPROACH Investigators
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R CooperbergPeter R Carroll
Jan 18, 2011·The Journal of Urology·Scott E EggenerAndrew J Stephenson
Apr 18, 2012·Annals of Internal Medicine·Richard B Weinberg
Jun 16, 2012·European Urology·Marc A Dall'EraMark S Soloway
Jul 18, 2012·Annals of Internal Medicine·Virginia A Moyer, UNKNOWN U.S. Preventive Services Task Force
Jul 20, 2012·The New England Journal of Medicine·Timothy J WiltUNKNOWN Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group
Nov 20, 2012·European Urology·Meelan BulMonique J Roobol
Mar 8, 2013·BJU International·Phillip M PierorazioJonathan I Epstein
May 11, 2013·The Journal of Urology·H Ballentine CarterAnthony L Zietman
Jun 19, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Debasish SundiEdward M Schaeffer
Oct 19, 2013·The Journal of Clinical Investigation·Michael C HaffnerSrinivasan Yegnasubramanian
Mar 7, 2014·The New England Journal of Medicine·Anna Bill-AxelsonJan-Erik Johansson
Mar 20, 2014·JAMA : the Journal of the American Medical Association·Julia H Hayes, Michael J Barry
Jul 16, 2014·JAMA Internal Medicine·Karen E HoffmanBenjamin D Smith
Aug 28, 2014·European Urology·Paul R WombleUNKNOWN Michigan Urological Surgery Improvement Collaborative
Sep 6, 2014·Journal of the National Comprehensive Cancer Network : JNCCN·Peter R CarrollUNKNOWN National comprehensive cancer network
Dec 17, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurence KlotzAndrew Loblaw

❮ Previous
Next ❯

Citations

Jan 28, 2016·Nature Reviews. Urology·Sophie M BruinsmaUNKNOWN Movember GAP3 consortium
Feb 3, 2016·Der Urologe. Ausg. A·Annika Herlemann, Christian G Stief
Mar 10, 2016·Nature Reviews. Urology·Jeffrey J TosoianStacy Loeb
Mar 10, 2016·Nature Reviews. Urology·Daniel A GalvãoRobert U Newton
Mar 27, 2016·Actas urologicas españolas·J L Ruiz-CerdáF Boronat-Tormo
Apr 3, 2016·International Journal of Cancer. Journal International Du Cancer·Friederike KendelWolfgang Gaissmaier
Jun 19, 2016·The Journal of Urology·Marc A Dall'Era
Jun 21, 2016·Future Oncology·Jamie N HoltzRajan T Gupta
Apr 14, 2016·Scandinavian Journal of Urology·Stacy LoebPär Stattin
Jul 14, 2016·Journal of Magnetic Resonance Imaging : JMRI·Simpa S SalamiArdeshir R Rastinehad
Jul 28, 2016·Journal of Medical Imaging and Radiation Oncology·Andrej Bece, Joseph Bucci
Aug 10, 2016·Current Urology Reports·Kae Jack TayThomas J Polascik
Oct 25, 2016·The Journal of Urology·Scott E Eggener
Oct 25, 2016·The Journal of Urology·Scott E EggenerAytekin Oto
Oct 25, 2016·The Journal of Urology·Hima Bindu MusunuruAndrew Loblaw
Jul 28, 2016·The Journal of Urology·Evan KovacAndrew J Stephenson
Oct 12, 2016·AJR. American Journal of Roentgenology·Tristan Barrett, Masoom A Haider
Jul 28, 2016·European Urology·H Ballentine Carter
Oct 26, 2016·Prostate Cancer and Prostatic Diseases·M MoschiniS F Shariat
Nov 30, 2016·Nature Reviews. Urology·Chad A Reichard, Eric A Klein
Mar 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arie P Dosoretz, James B Yu
Feb 18, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark C ScholzJeffrey S Turner
Sep 2, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony V D'Amico
Feb 28, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony V D'Amico

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.